Cart22 Cells
B Cell Lymphomas
University of PennsylvaniaCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the B Cell Lymphomas cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Idarubicine Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 4 | BBB |
azd6738 AstraZeneca | Phase 1 | CC |
CART22-65s University of Pennsylvania | Phase 1 | CC |
Actr T Cell Product Cogent Biosciences, Inc. | D |
Same molecule, other indications
Cart22 Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →